Clinical Study

A Study To Evaluate The Safety And Effectiveness Of Cotadutide Given By Subcutaneous Injection In Adult Patients With Non-Alcoholic Steatohepatitis (Nash) With Scarring But Not Cirrhosis.

Posted Date: Dec 14, 2022

  • Investigator: Kenneth Sherman
  • Specialties:
  • Type of Study: Drug

The study drug cotadutide has shown promise in treating Non-Alcoholic Steatohepatitis also known as NASH in previous studies. This study aims to study that it is safe and effective with subjects who are currently diagnosed with NASH and have mild to moderate scarring of their liver. Subjects will be randomly assigned to real drug in 2 different doses or placebo. Subjects must be willing to undergo testing to determine qualification for and monitoring of safety during the study.


Adult. Currently Diagnosed With Nash. Liver Scarring But Not Cirrhosis


Nash, Fatty Liver Disease

For More Information:

Elisa Wynn

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.